DICE Therapeutics (DICE) Stock Forecast, Price & News

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DICE Therapeutics in the last year. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DICE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DICE, but not buy additional shares or sell existing shares.
View DICE analyst ratings or view top-rated stocks.

13 brokerages have issued 12-month target prices for DICE Therapeutics' shares. Their DICE share price forecasts range from $48.00 to $77.00. On average, they expect the company's stock price to reach $62.40 in the next year. This suggests a possible upside of 31.2% from the stock's current price.
View analysts price targets for DICE or view top-rated stocks among Wall Street analysts.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our DICE earnings forecast.

DICE Therapeutics, Inc. (NASDAQ:DICE) released its earnings results on Tuesday, August, 8th. The company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.65) by $0.09.

ETFs with the largest weight of DICE Therapeutics (NASDAQ:DICE) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), AltShares Merger Arbitrage ETF (ARB), First Trust Merger Arbitrage ETF (MARB), ProShares Merger ETF (MRGR), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and AltShares Event-Driven ET (EVNT).

(DICE) raised $160 million in an initial public offering on Wednesday, September 15th 2021. The company issued 10,000,000 shares at $15.00-$17.00 per share.

DICE Therapeutics trades on the NASDAQ under the ticker symbol "DICE."

DICE Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.06%), Alpine Associates Management Inc. (4.43%), Driehaus Capital Management LLC (4.27%), Braidwell LP (2.16%), KRYGER CAPITAL Ltd (1.85%) and State Street Corp (1.75%). Insiders that own company stock include James Paul Scopa, John R Jacobsen, Kevin Judice, Lu Timothy, Northpond Ventures Gp, Llc, Ra Capital Management, LP, Richard H Scheller and Scott M Robertson.
View institutional ownership trends.

One share of DICE stock can currently be purchased for approximately $47.55.

DICE Therapeutics (NASDAQ:DICE) has a market capitalization of $2.27 billion and generates $1.13 million in revenue each year. The company earns $-83,890,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis.

DICE Therapeutics' mailing address is 279 E. GRAND AVENUE SUITE 300 LOBBY B, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.dicemolecules.com. The company can be reached via phone at 650-566-1420 or via email at investors@dicetx.com.